Cite
HARVARD Citation
Saba, N. et al. (2019). Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral oncology. pp. 7-14. [Online].